Data obtained from an in vivo study using different immunisation schedules indicate that these human anti-Id scFv can induce an effective anti-HER-2/neu humoral response in experimental animals and suggest that they could serve as a surrogate for the tumour antigen HER-2/neu. The gene discussed is ERBB2; the disease is neoplasm.